An experimental melanoma vaccine has stirred both hope and disappointment. IO Biotech’s cancer vaccine, Cylembio, combined with Merck’s blockbuster drug Keytruda, extended progression‑free survival in patients to 19.4 months versus 11 months for Keytruda alone reuters.com. That suggests the shot could meaningfully delay disease progression in advanced melanoma. However, the Phase II/III trial narrowly missed its primary statistical endpoint, sending IO Biotech’s shares tumbling reuters.com. Analysts caution that the dataset is small, with just 157 patients enrolled, making it difficult to draw definitive conclusions. Even so, safety appeared acceptable, and nearly half of the trial’s participants had previously received other immunotherapies reuters.com.
The miss doesn’t necessarily doom the vaccine. IO Biotech plans to meet with the U.S. Food & Drug Administration to discuss a potential approval pathway, arguing that the 8.4‑month benefit is clinically meaningful reuters.com. With 1.5 million Americans living with melanoma and existing therapies such as Keytruda and Bristol Myers Squibb’s Opdivo sometimes failing, doctors are eager for new options. If regulators agree that Cylembio’s risk‑benefit profile is positive, the therapy could still reach patients. For now, investors and oncologists alike await further data from a larger pivotal trial.
